Skip to content

Celso Arango

3 papers in the library · 326 citations · publishing 2020-2025

Papers

The lived experience of psychosis: a bottom-up review co-written by experts by experience and academics.

World psychiatry : official journal of the World Psychiatric Association (WPA) June 1, 2022 Paolo Fusar-Poli, Andrés Estradé, Giovanni Stanghellini et al. 225 citations

Psychosis unfolds through distinct stages, each with its own core existential experiences. Early phases (premorbid and prodromal) involve loss of common sense, perplexity, lack of immersion in the world, heightened salience, a feeling that something important is about to happen, perturbation of the sense of self, and a need to hide inner turmoil. The first episode brings transitory relief from delusions, intense self-referentiality, permeated self-world boundaries, internal noise, and dissolution of self with social withdrawal. Later stages (relapsing and chronic) involve grieving losses, feeling split, and struggling to accept inner chaos, a new self, diagnosis, and uncertain future. Treatment experiences include both positive and negative aspects, with recovery understood as reconstructing personhood and re-establishing bonds toward meaningful goals.

Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study

Psychological Medicine March 18, 2020 Diego Quattrone, Laura Ferraro, Giada Tripoli et al. 89 citations

Daily use of high-potency cannabis is associated with more positive symptoms and fewer negative symptoms in first-episode psychosis patients. Among 901 patients and 1,235 controls across six European countries, those who used high-potency cannabis daily had the highest scores on positive symptoms, while negative symptoms were more common in patients who never used cannabis. Psychotic experiences in controls were linked to current cannabis use but not to lifetime use. Depressive symptoms showed no differences related to cannabis use in either group.

Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology April 1, 2025 Eduard Vieta, Nahida Ahmed, Celso Arango et al. 12 citations

Patients with treatment-resistant depression who received esketamine nasal spray experienced 43.2% more weeks with functional remission over 32 weeks compared to those taking quetiapine extended release, a difference of 2.0 weeks. Esketamine also led to an 11.9% reduction in productivity loss due to absenteeism and a 14.2% reduction in overall work productivity loss. Both treatments were taken alongside an ongoing SSRI or SNRI. The findings suggest that esketamine provides greater improvements in daily functioning and workplace productivity for this patient group.